Semaglutide
GLP-1 / Metabolic research-only
Mechanism
No mechanism summary on file.
Identification
| CAS number | 910463-68-2 |
|---|---|
| Molecular formula | C187H291N45O59 |
Safety
Same active ingredient as FDA-approved Ozempic, Wegovy, and Rybelsus (Novo Nordisk). FDA resolved the semaglutide shortage February 21, 2025; 503A enforcement discretion ended February 18, 2025 and 503B ended May 22, 2025. On April 30, 2026 FDA proposed permanently excluding semaglutide from the 503B Bulks List. Research-market channel is unregulated and is not FDA-controlled despite molecular identity. Per JMIR 2024 (Ashraf/Mackey), measured purity of test purchases from no-prescription research vendors ranged from 7.7% to 14.37% against labeled 99%, with endotoxin contamination of 2.16-8.95 EU/mg.
Vendors selling Semaglutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Nuscience Peptides | — | — | — | 60 |
| Elite Research USA | — | — | — | 53 |
| Skye Peptides | — | — | — | 53 |
| Peptide Sciences | — | — | — | 26 |
Research
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
Hathaway JT, Shah MP, Hathaway DB, et al. · JAMA Ophthalmol (2024) ·
source → Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Lingvay I, Deanfield J, et al. · Nat Med (2024) · rct
source → A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert Opin Pharmacother (2024) · review
source → Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, Krauthamer M, Bjalme-Evans M · J Investig Med (2022) · review
source → Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM · J ASEAN Fed Endocr Soc (2022) · meta-analysis
source → Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, et al. · Lancet (2021) · rct
source → Safety of Semaglutide.
Smits MM, Van Raalte DH · Front Endocrinol (Lausanne) (2021) · review
source → Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, Salinas CG, Paulsen SJ, et al. · JCI Insight (2020) ·
source → The Discovery and Development of Liraglutide and Semaglutide.
Knudsen LB, Lau J · Front Endocrinol (Lausanne) (2019) · review
source → Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol (2018) · rct
source →